Skip to main content
HCPCS J3260 · Level II · Part B drug

J3260: tobramycin sulfate, HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J3260

Billing unit
80 MG
Tobramycin sulfate injection
ASP payment limit
$2.345
October 2026; +7.3% vs July 2026
Practitioner MUE
8
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J3260 is the Level II code for Injection, tobramycin sulfate, up to 80 mg, billed per 80 MG. The Medicare Part B ASP payment limit for October 2026 is $2.345 per billing unit, up 7.3% from July 2026. The practitioner MUE allows up to 8 units per date of service (MAI 3), so a full 8-unit day is $18.76 at the current limit. Under OPPS it carries status indicator N. J3260 is billed in units of 80 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names tobramycin: J7682 (CMS descriptor names "administered through dme"; inhalation route; solution, unit dose; billed per 300 mg). The ASP crosswalk maps 19 NDCs to it, sold as Tobramycin Sulfate, Tobramycin by Pfizer Inc, Baxter Healthcare Corporation, XGen Pharmaceuticals DJB, Inc. No current Billing and Coding Article lists J3260, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J3260 at $2.345 per 80 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $2.186 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J3260
QuarterPayment limitPerCoinsurance
October 2026$2.34580 MG20%
July 2026$2.18680 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 19 NDCs from 10 labelers to J3260. Report the NDC in the claim's drug segment and bill the number of J3260 units that equals the quantity administered divided by 80 MG; the last column gives units per full package.

NDCs that crosswalk to J3260
NDCDrug nameLabelerPackage sizeBilling units / package
00409-3578-01Tobramycin SulfatePfizer Inc2 × 2525
36000-0242-01Tobramycin SulfateBaxter Healthcare Corporation1 × 115
36000-0244-25Tobramycin SulfateBaxter Healthcare Corporation2 × 2525
39822-0412-01Tobramycin SulfateXGen Pharmaceuticals DJB, Inc.1 × 115
39822-0412-06Tobramycin SulfateXGen Pharmaceuticals DJB, Inc.1 × 690
55150-0470-06Tobramycin SulfateEugia US LLC1 × 690
63323-0303-51Tobramycin SulfateFreseniUS Kabi USA, LLC1 × 690
63323-0303-55Tobramycin SulfateFreseniUS Kabi USA, LLC1 × 690
63323-0305-02Tobramycin SulfateFreseniUS Kabi USA, LLC2 × 257
63323-0306-02Tobramycin SulfateFreseniUS Kabi USA, LLC2 × 2525
63323-0306-30Tobramycin SulfateFreseniUS Kabi USA, LLC30 × 10150
67457-0428-30Tobramycin SulfateMylan Institutional LLC30 × 10150
67457-0473-22Tobramycin SulfateMylan Institutional LLC2 × 2525
70436-0110-56Tobramycin SulfateSlate Run Pharmaceuticals1 × 690
70436-0110-80Tobramycin SulfateSlate Run Pharmaceuticals1 × 115
70700-0173-22TobramycinXiromed, LLC1 × 115
70700-0173-86Tobramycin SulfateXiromed, LLC1 × 690
72266-0163-06Tobramycin SulfateFosun Pharma USA Inc.1 × 690
72603-0160-06Tobramycin SulfateNorthstar RxLLC1 × 690

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J3260. For practitioners the limit is 8 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J3260 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services83 Date of Service Edit: ClinicalClinical: Data
Facility outpatient hospital123 Date of Service Edit: ClinicalClinical: Data
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J3260 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J3260 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J3260 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J3260 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J3260 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J3260 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J3260 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J3260 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J3260

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J3260

What does HCPCS code J3260 describe?

J3260 is defined by CMS as "Injection, tobramycin sulfate, up to 80 mg". Each billing unit represents 80 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J3260 a CPT code?

No. J3260 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as tobramycin sulfate; CPT codes are five-character codes maintained by the AMA. On a Part B claim J3260 reports the drug itself in 80 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J3260 in October 2026?

The ASP-based payment limit is $2.345 per 80 MG, with 20% beneficiary coinsurance. The July 2026 limit was $2.186. Commercial payers use their own fee schedules.

How many units of J3260 can be billed per day?

The practitioner Medically Unlikely Edit is 8 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). The facility outpatient MUE is 12. MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Clinical: Data" as the rationale.

Which NDCs map to J3260?

The October 2026 ASP crosswalk lists 19 NDCs from 10 labelers: Tobramycin Sulfate (Pfizer Inc); Tobramycin Sulfate (Baxter Healthcare Corporation); Tobramycin Sulfate (XGen Pharmaceuticals DJB, Inc.); Tobramycin Sulfate (Eugia US LLC). For example NDC 00409-3578-01 (package size 2) equals 25 billing units of J3260.

Does J3260 have NCCI bundling edits?

No active practitioner PTP pairs list J3260 as a column-1 or column-2 code in the v323r0 release.

J3260 vs J7682: what is the difference?

Both are HCPCS Level II codes whose descriptor names tobramycin. What sets J7682 apart: CMS descriptor names "administered through dme"; inhalation route; solution, unit dose; billed per 300 mg. J3260 is billed per 80 mg, limit $2.345, MUE 8; J7682 is billed per 300 mg, limit $11.404, MUE 2. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.